|
72
|
241
|
6cznA |
Estrogen receptor alpha ligand binding domain y537s mutant in complex with z2ohtpe and a glucocorticoid receptor-interacting protein 1 nr box ii peptide |
|
83
|
221
|
6a6kA |
Crystal structure of estrogen-related receptor-3 (err-gamma) ligand binding domain with dn201000 |
|
78
|
237
|
5yd6A |
Crystal structure of pg-bound nurr1-lbd |
|
94
|
242
|
3up0A |
Nuclear receptor daf-12 from hookworm ancylostoma ceylanicum in complex with (25s)-delta7-dafachronic acid |
|
91
|
269
|
3s9sA |
Ligand binding domain of ppargamma complexed with a benzimidazole partial agonist |
|
71
|
325
|
5uanA |
Crystal structure of multi-domain rar-beta-rxr-alpha heterodimer on dna |
|
93
|
228
|
6a5yA |
Crystal structure of human fxr/rxr-lbd heterodimer bound to hnc143 and 9cra and src1 |
|
87
|
229
|
6a5xA |
Fxr-lbd with hnc180 and src1 |
|
85
|
243
|
5tm1A |
Crystal structure of the er-alpha ligand-binding domain (y537s) in complex with 2,5-bis(2-fluoro-4-hydroxyphenyl)thiophene 1-oxide |
|
89
|
244
|
5tlpA |
Crystal structure of the er-alpha ligand-binding domain (y537s) in complex with the obhs-bsc analog, 3-fluorophenyl (1r,2r,4s)-5-(4-hydroxyphenyl)-6-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonate and 3-methyl-6-phenyl-3h-imidazo[4,5-b]pyridin-2-amine |
|
91
|
228
|
5q0rA |
Ligand binding to farnesoid-x-receptor |
|
100
|
247
|
5nfpA |
Glucocorticoid receptor in complex with budesonide |
|
85
|
229
|
5q17A |
Ligand binding to farnesoid-x-receptor |
|
86
|
229
|
5q1hA |
Ligand binding to farnesoid-x-receptor |
|
99
|
252
|
5ni8A |
Ligand complex of rorg lbd |
|
91
|
245
|
5tlyA |
Crystal structure of the er-alpha ligand-binding domain (y537s) in complex with 3,4-bis(2-fluoro-4-hydroxyphenyl)thiophene 1,1-dioxide |
|
95
|
248
|
5nftA |
Glucocorticoid receptor in complex with azd5423 |
|
88
|
230
|
5q0oA |
Ligand binding to farnesoid-x-receptor |
|
104
|
250
|
5ni5A |
Ligand complex of rorg lbd |
|
86
|
246
|
5tltA |
Crystal structure of the er-alpha ligand-binding domain (y537s) in complex with octane-1,8-diyl bis(2,3-bis(4-hydroxyphenyl)pentanoate) |
|
91
|
228
|
5q0wA |
Ligand binding to farnesoid-x-receptor |
|
81
|
229
|
5q0tA |
Ligand binding to farnesoid-x-receptor |
|
85
|
229
|
5q0nA |
Ligand binding to farnesoid-x-receptor |
|
87
|
230
|
5q16A |
Ligand binding to farnesoid-x-receptor |
|
89
|
230
|
5q0yA |
Ligand binding to farnesoid-x-receptor |
|
93
|
254
|
5mwpA |
The structure of mr in complex with azd9977. |
|
100
|
254
|
5mwyA |
The structure of mr in complex with eplerenone. |
|
93
|
225
|
5m96A |
Synthesis and biological evaluation of new triazolo and imidazolopyridine rorgt inverse agonists |
|
82
|
230
|
5mkjA |
Crystal structure of the retinoid x receptor alpha in complex with synthetic honokiol derivative 9 and a fragment of the tif2 co-activator. |
|
83
|
228
|
5mkuA |
Crystal structure of the retinoid x receptor alpha in complex with synthetic honokiol derivative 4 and a fragment of the tif2 co-activator. |
|
81
|
229
|
5mmwA |
Crystal structure of the retinoid x receptor alpha in complex with synthetic honokiol derivative 6 and a fragment of the tif2 co-activator. |
|
84
|
229
|
5mj5A |
Crystal structure of the retinoid x receptor alpha in complex with synthetichonokiol derivative 3 and a fragment of the tif2 co-activator. |
|
83
|
230
|
5lyqA |
Crystal structure of the retinoic acid receptor alpha in complex with a synthetic spiroketal agonist and a fragment of the tif2 co-activator. |
|
94
|
299
|
5lgaA |
Structural analysis and biological activities of bxl0124, a gemini analog of vitamin d |
|
88
|
244
|
5lwpA |
Discovery of phenoxyindazoles and phenylthioindazoles as rorg inverse agonists |
|
96
|
236
|
5m24A |
Rarg mutant-s371e |
|
95
|
248
|
5l7gA |
Mcr in complex with ligand |
|
99
|
248
|
5l7eA |
Mcr in complex with ligand |
|
96
|
268
|
5lsgA |
Ppargamma complex with the betulinic acid |
|
94
|
245
|
5krcA |
Crystal structure of the er-alpha ligand-binding domain (y537s) in complex with zearalenone |
|
90
|
246
|
5kr9A |
Crystal structure of the er-alpha ligand-binding domain (y537s) in complex with coumestrol |
|
79
|
244
|
5krkA |
Crystal structure of the er-alpha ligand-binding domain (y537s) in complex with 4,4'-((5-bromo-2,3-dihydro-1h-inden-1-ylidene)methylene)diphenol |
|
87
|
243
|
5kroA |
Crystal structure of the er-alpha ligand-binding domain (y537s) in complex with the methyl(phenyl)amino-substituted estrogen, (8r,9s,13s,14s,17s)-13-methyl-17-(methyl(phenyl)amino)-7,8,9,11,12,13,14,15,16,17-decahydro-6h-cyclopenta[a]phenanthren-3-ol |
|
79
|
247
|
5kyaB |
Brain penetrant liver x receptor (lxr) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core |
|
86
|
244
|
5krhA |
Crystal structure of the er-alpha ligand-binding domain (y537s) in complex with 16-benzylidene estrone |
|
89
|
244
|
5kriA |
Crystal structure of the er-alpha ligand-binding domain (y537s) in complex with 16b-benzyl 17b-estradiol |
|
95
|
260
|
5kyjA |
Brain penetrant liver x receptor (lxr) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core |
|
88
|
245
|
5krmA |
Crystal structure of the er-alpha ligand-binding domain (y537s) in complex with the a-cd ring estrogen, (1s,7as)-5-(2,5-difluoro-4-hydroxyphenyl)-7a-methyl-2,3,3a,4,7,7a-hexahydro-1h-inden-1-ol |
|
92
|
237
|
5l11A |
Human liver receptor homologue-1 (lrh-1) bound to rjw100 and a fragment of tif-2 |
|
85
|
247
|
5kyjB |
Brain penetrant liver x receptor (lxr) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core |
